Two years ago, Alex Jutca was scrolling the internet when he came across Nicholas Reville’s Substack. The founder of an addiction policy organization, Reville had posted articles including one that asked: “How can government drive more medication development for addiction?”
Jutca, director of the Allegheny County Department of Human Services, was intrigued.
“He said, ‘We need an Operation Warp Speed but for addiction medicine,’” Jutca recalled. “That was a message that deeply resonated with me. There is just a real need for effective policy solutions.”
He reached out to Reville, and a partnership began. It ultimately led to the creation of a first-of-its-kind, $13 million trial that will examine how weekly injections of the popular GLP-1 drug semaglutide (sold under the brand names Ozempic and Wegovy) affect Allegheny County residents with addiction.
The study will be funded by a Houston-based philanthropic group, Arnold Ventures.
While research on other diseases, such as cancer, have yielded hundreds of viable drug treatments, the Food and Drug Administration has approved only three medicines for opioid use disorder — methadone, buprenorphine and naltrexone — and a meager 2% of people with alcohol use disorder seek treatment in that realm.
Early results of GLP-1 trials on people with diabetes that showed they also happened to drink less clued researchers into exploring the drug’s role in substance abuse.
“More and more, we’re finding out that a lot of these areas in the brain that mediate drug reward and conditioning have been really in a way affected by the GLP-1,” said Antoine Douaihy, senior academic director of addiction medicine services at UPMC Western Psychiatric Hospital and a trial leader.
One such study, published in the Lancet in May, found that participants taking GLP-1s reduced the number of days they drank alcohol by 41% compared to a control group.
Another by researchers at the St. Louis, Mo., VA found that veterans with diabetes given GLP-1 drugs saw reduced risk of harm from alcohol, cannabis, cocaine, nicotine and opioid use disorders, compared to veterans on a standard diabetes drug. And preliminary findings see similar results in animal models.
Scientists think GLP-1 drugs act on the brain’s reward system, as opposed to targeting one specific addiction pathway. This means the medications could hold potential for managing addiction and cravings during a time when few treatments exist for people with substance use disorders.
“The GLP-1 drug is putting the lid on that mechanism that suppresses the surge in dopamine, that magnetic pull, that literally pulls people toward substances,” said Ziyad Al-Aly, chief of research and development at VA St. Louis Health Care System, clinical epidemiologist at Washington University in St. Louis and senior author on the VA study.
The local trial, a partnership between Western Psychiatric Hospital, County DHS and Reville’s San Francisco-based Center for Addiction Science, Policy and Research will enroll 1,200 Allegheny County residents with either opioid or alcohol use disorder. All of the cohort will get standard addiction treatment of therapy and social support, while half of the group will also receive semaglutide.
The trial aims to include people at high risk of involvement with the criminal justice system, who experts believe can most benefit from new therapies.
“We intend to run the trial with people who are typically excluded from research,” said Reville.

Understanding that the disease of addiction touches many corners of society — housing, child well-being, food security, crime — Reville and Jutca seek to optimize the benefits of treating addiction, hoping to see ripple effects in other socioeconomic trends.
They believe that, if the treatment works, it will ultimately save the county money and could have secondary benefits by keeping people out of jail and driving down costs to manage homelessness.
“In many ways, this is more of an economic trial than a medical trial,” Reville said. “We’re designing this trial to show that, in the real world, this intervention helps people, helps communities and saves money.”
Reville was impressed by Allegheny County’s robust data monitoring and record-keeping systems, far above what he’s seen other counties have, he said.
Many of the county’s social services are interconnected via these systems. For instance, if an inmate is administered buprenorphine through Allegheny County Jail or a person receives housing assistance from one of the county’s programs, the individual’s path and services accessed are trackable.
This will allow the trial team to intervene if a person drops out of the trial without notification or disappears and is later found to have been arrested or struggling with housing.
“It gives us the ability to look at the downstream consequences of addiction, and what it costs the county,” said Reville.
Al-Aly is not involved in the current trial but is excited to see that Jutca and Reville are viewing addiction from a broad perspective.
“Addiction does not come in a vacuum,” he said. “It’s commendable that there is an effort in this trial to holistically evaluate the effectiveness of GLP-1 on addiction and the social justice ramifications.”
It will be crucial for study leaders to continuously monitor vitals, bloodwork and side effects throughout the trial, especially because participants are more likely to be unstable and in poor health.
Because they slow gastric motility, GLP-1 drugs carry intense gastrointestinal side effects, namely nausea, bloating, cramping and constipation. Those with an opioid use disorder are at higher risk of these side effects because opioids also slow motility and lead to constipation.
Researchers will also want to ensure participants are not becoming malnourished or losing too much weight, so they’re implementing a body mass index minimum for eligible participants.
Inflammation of the pancreas will be another important complication to watch for, said Al-Aly, as around one in four people with alcohol use disorder have acute pancreatitis, per Merck. He hopes to see an additional safety board of independent scientists added to the trial, who can monitor the most concerning possible complications.
“They’re gonna be monitored very closely, and the advantages must be weighed against adverse side effects,” said Douaihy. “This is a totally new territory we’re tapping into.”

Al-Aly also suggested embedding nutritional and exercise guidance into the trial protocol, as people on GLP-1 drugs are likely to lose muscle and bone mass in addition to body fat, and are susceptible to malnourishment from a lack of absorption of vitamins and minerals.
“People with an addiction disorder may be thin in the first place,” he said, and losing more weight and muscle may exacerbate frailty and emaciation. “Those things are really key to think about.”
The team is still working out who will be eligible for the study and any conditions that might exclude someone from participating. They’re hoping to start recruiting people in January, and will follow patients for one year.
“This is a truly groundbreaking study, and it’s only possible with the partners in Allegheny County,” said Reville. ”I think it has world-changing implications if it’s successful.”

Reville said he’s running a similar pilot study in Providence, R.I., which has enrolled previously incarcerated women now living in sober housing. Its early success, he said, informed the development of the Allegheny County trial.
His team is seeing “remarkable transformations” in these women, whose stability has skyrocketed after the GLP-1 drugs dissolved their cravings.
“Part of what we’re seeing is when you take away the addiction, these are intelligent people who know what they need to be doing,” said Reville. “They start doing a great job in everything they need to do on their own. We just need to quiet that noise.”





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.